top of page

Cambridge, UK based LoQus23 Therapeutics will use a small molecule allosteric inhibitor of MutSβ to treat Huntington's

  • Jan 29, 2025
  • 1 min read

Co-Founder and CEO David Reynolds describes why LoQus23 is taking a small molecule approach to neurodegenerative diseases and why they believe stopping DNA instability is the right approach to Huntington's and other conditions.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page